Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $16.75.

Several research analysts have recently commented on the stock. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Wells Fargo & Company cut their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th.

Amicus Therapeutics Trading Up 0.1 %

Amicus Therapeutics stock traded up $0.01 during midday trading on Monday, reaching $8.00. 4,769,318 shares of the stock traded hands, compared to its average volume of 2,535,386. The firm has a market cap of $2.46 billion, a PE ratio of -44.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company has a 50-day simple moving average of $9.16 and a two-hundred day simple moving average of $9.88. Amicus Therapeutics has a 12-month low of $7.72 and a 12-month high of $12.65.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. HealthInvest Partners AB lifted its position in shares of Amicus Therapeutics by 18.6% during the 4th quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company's stock worth $3,076,000 after buying an additional 51,368 shares during the last quarter. Wellington Management Group LLP raised its stake in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock worth $255,936,000 after acquiring an additional 2,856,101 shares in the last quarter. Tempus Wealth Planning LLC purchased a new stake in Amicus Therapeutics in the fourth quarter valued at $259,000. Neo Ivy Capital Management acquired a new position in Amicus Therapeutics in the third quarter valued at $702,000. Finally, Intech Investment Management LLC boosted its stake in Amicus Therapeutics by 59.7% in the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock valued at $1,175,000 after acquiring an additional 46,633 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.